SCHEMBL31593094

SCHEMBL31593094

CC(=O)N[C@H]1Cc2ccc(cc2)Oc2ccc(cc2)C[C@@H](C(=O)N[C@H](CCCNC(=N)N)C(=O)c2nc3ccccc3s2)NC(=O)[C@H](CC(C)C)NC1=O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPN P05981 16/20 0.83
▸ ST14 Q9Y5Y6 16/20 0.83
▸ TMPRSS2 O15393 14/20 0.83
▸ HGFAC Q04756 14/20 0.83
▸ F2 P00734 14/20 0.77
▸ F10 P00742 5/20 0.77
▸ PSMB11 A5LHX3 1/20 0.48
▸ PSMA7 O14818 1/20 0.48
▸ PSMB1 P20618 1/20 0.48
▸ PSMA1 P25786 1/20 0.48
▸ PSMA2 P25787 1/20 0.48
▸ PSMA3 P25788 1/20 0.48
▸ PSMA4 P25789 1/20 0.48
▸ PSMB8 P28062 1/20 0.48
▸ PSMB9 P28065 1/20 0.48
▸ PSMA5 P28066 1/20 0.48
▸ PSMB4 P28070 1/20 0.48
▸ PSMB6 P28072 1/20 0.48
▸ PSMB5 P28074 1/20 0.48
▸ PSMB10 P40306 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31593139 1.00 HPN (0.83) HPNST14TMPRSS2HGFACF2
SCHEMBL31593124 0.96 HPN (0.84) HPNST14TMPRSS2HGFACF2
SCHEMBL31593133 0.96 HPN (0.84) HPNST14TMPRSS2HGFACF2
SCHEMBL31593087 0.96 HPN (0.84) HPNST14TMPRSS2HGFACF2
SCHEMBL31593092 0.96 HPN (0.84) HPNST14TMPRSS2HGFACF2
SCHEMBL22850400 0.91 HPN (0.84) HPNST14TMPRSS2HGFACF2
SCHEMBL31593138 0.91 HPN (0.84) HPNST14TMPRSS2HGFACF2
SCHEMBL31593114 0.91 HPN (0.84) HPNST14TMPRSS2HGFACF2
SCHEMBL31593090 0.91 HPN (0.84) HPNST14TMPRSS2HGFACF2
SCHEMBL31593136 0.90 HPN (0.85) HPNST14TMPRSS2HGFACF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171495-A1 MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION WASHINGTON UNIVERSITY 2025-05-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171495-A1 MUTLI-TARGETED SERINE PROTEASE INHIBITORS FOR TREATMENT OF CANCER AND VIRAL INFECTION TMPRSS2, PRSS1, PRSS2 HPN 13/4885ST14 84/4885TMPRSS2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback